Recombinant Protein Drugs Market Report

Europe Recombinant Protein Drugs Market Size, Status and Forecast 2014-2026

  • POSTDATE：Jun 26, 2020
  • PAGES：189
  • REPORT CODE：GMM586536
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The Recombinant Protein Drugs market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 2.6% during the forecast period. Focusing on the Europe market, this report analyzes the specific consumption structure, such as types and end users. In order to present the status of the circulation of this product in different Europe countries, this report covers top export and import countries to confirm the potential markets. Leading countries such as Germany, UK, France, Italy, Spain, Poland, Russia, Switzerland, Turkey, Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden), Benelux (Belgium, Netherlands, and Luxembourg), Baltic States (Estonia, Latvia, and Lithuania) and other countries, the market status and consumption potential of these countries are covered in the research, providing valuable opinions of strategic adjustments for existing groups and new entrants.

    The Snapshot of Europe Recombinant Protein Drugs Market Segmentations:

    By Player:

    • Eli Lilly

    • SL PHARM

    • Roche

    • Abcam

    • Kyowa Hakko Kirin

    • Sanofi

    • Amgen

    • Merck Serono

    • Pharmingen

    • Dongbao Pharm

    • NCPC

    • Novo Nordisk

    • Heng Rui

    • Ankebio

    • GenSci

    • Ortho Biotech

    By Type:

    • Recombinant DNA

    • Recombinant RNA

    By End-User:

    • Polymer and Petrochemicals

    • Pharmaceuticals

    • Electronics

    • Agrochemicals

    • Others

    By Region:

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Poland

    • Russia

    • Switzerland

    • Turkey

    • Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden)

      • Denmark

      • Finland

      • Norway

      • Sweden

      • Iceland

    • Benelux (Belgium, Netherlands, and Luxembourg)

      • Belgium

      • Netherlands

      • Luxembourg

    • Baltic States (Estonia, Latvia, and Lithuania)

      • Estonia

      • Latvia

      • Lithuania

  • Table of Contents

    1 Report Overview

    • 1.1 Product Definition and Scope

    • 1.2 PEST (Political, Economic, Social and Technological) Analysis of Recombinant Protein Drugs Market

    • 1.3 Market Segment by Type

    • 1.3.1 Europe Recombinant Protein Drugs Market Size and Growth Rate of Recombinant DNA from 2014 to 2026

    • 1.3.2 Europe Recombinant Protein Drugs Market Size and Growth Rate of Recombinant RNA from 2014 to 2026

    • 1.4 Market Segment by Application

    • 1.4.1 Europe Recombinant Protein Drugs Market Size and Growth Rate of Polymer and Petrochemicals from 2014 to 2026

    • 1.4.2 Europe Recombinant Protein Drugs Market Size and Growth Rate of Pharmaceuticals from 2014 to 2026

    • 1.4.3 Europe Recombinant Protein Drugs Market Size and Growth Rate of Electronics from 2014 to 2026

    • 1.4.4 Europe Recombinant Protein Drugs Market Size and Growth Rate of Agrochemicals from 2014 to 2026

    • 1.4.5 Europe Recombinant Protein Drugs Market Size and Growth Rate of Others from 2014 to 2026

    • 1.5 Market Segment by Regions

      • 1.5.1 Germany Recombinant Protein Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.2 UK Recombinant Protein Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.3 France Recombinant Protein Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.4 Italy Recombinant Protein Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.5 Spain Recombinant Protein Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.6 Poland Recombinant Protein Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.7 Russia Recombinant Protein Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.8 Switzerland Recombinant Protein Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.9 Turkey Recombinant Protein Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Recombinant Protein Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.11 Benelux (Belgium, Netherlands, and Luxembourg) Recombinant Protein Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.12 Baltic States (Estonia, Latvia, and Lithuania) Recombinant Protein Drugs Market Size and Growth Rate from 2014 to 2026

    2 Market Trends and Competitive Landscape

    • 2.1 Market Trends and Dynamics

      • 2.1.1 Market Challenges and Restraints

      • 2.1.2 Market Opportunities and Potentials

      • 2.1.3 Mergers and Acquisitions

    • 2.2 Competitive Landscape Analysis

      • 2.2.1 Industrial Concentration Analysis

      • 2.2.2 Porter's Five Forces Analysis of the Industry

      • 2.2.3 SWOT Analysis for New Entrants

    3 Segmentation of Recombinant Protein Drugs Market by Types

    • 3.1 Products Development Trends of Different Types

    • 3.2 Commercial Products Types of Major Venders

    • 3.3 Competitive Landscape Analysis of Different Types

    • 3.4 Market Size of Recombinant Protein Drugs by Major Types

      • 3.4.1 Market Size and Growth Rate of Recombinant DNA

      • 3.4.2 Market Size and Growth Rate of Recombinant RNA

    4 Segmentation of Recombinant Protein Drugs Market by End-Users

    • 4.1 Downstream Client Analysis by End-Users

    • 4.2 Competitive Landscape Analysis of Different End-Users

    • 4.3 Market Potential Analysis of Different End-Users

    • 4.4 Market Size of Recombinant Protein Drugs by Major End-Users

      • 4.4.1 Market Size and Growth Rate of Polymer and Petrochemicals for Construction

      • 4.4.2 Market Size and Growth Rate of Pharmaceuticals for Construction

      • 4.4.3 Market Size and Growth Rate of Electronics for Construction

      • 4.4.4 Market Size and Growth Rate of Agrochemicals for Construction

      • 4.4.5 Market Size and Growth Rate of Others for Construction

    5 Market Analysis by Major Regions

    • 5.1 Europe Recombinant Protein Drugs Production Analysis by Top Regions

    • 5.2 Europe Recombinant Protein Drugs Consumption Analysis by Top Regions

    • 5.3 Europe Recombinant Protein Drugs Production, Import, Consumption and Export Analysis by Regions

      • 5.3.1 Germany Recombinant Protein Drugs Production, Import, Consumption and Export Analysis

      • 5.3.2 UK Recombinant Protein Drugs Production, Import, Consumption and Export Analysis

      • 5.3.3 France Recombinant Protein Drugs Production, Import, Consumption and Export Analysis

      • 5.3.4 Italy Recombinant Protein Drugs Production, Import, Consumption and Export Analysis

      • 5.3.5 Spain Recombinant Protein Drugs Production, Import, Consumption and Export Analysis

      • 5.3.6 Poland Recombinant Protein Drugs Production, Import, Consumption and Export Analysis

      • 5.3.7 Russia Recombinant Protein Drugs Production, Import, Consumption and Export Analysis

      • 5.3.8 Switzerland Recombinant Protein Drugs Production, Import, Consumption and Export Analysis

      • 5.3.9 Turkey Recombinant Protein Drugs Production, Import, Consumption and Export Analysis

      • 5.3.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Recombinant Protein Drugs Production, Import, Consumption and Export Analysis

      • 5.3.11 Benelux (Belgium, Netherlands, and Luxembourg) Recombinant Protein Drugs Production, Import, Consumption and Export Analysis

      • 5.3.12 Baltic States (Estonia, Latvia, and Lithuania) Recombinant Protein Drugs Production, Import, Consumption and Export Analysis

    6 Product Circulation of Recombinant Protein Drugs Market among Top Countries

    • 6.1 Top 5 Export Countries in Recombinant Protein Drugs Market from 2014 to 2019

      • 6.1.1 Top 5 Export Countries’ Export Value Analysis in Recombinant Protein Drugs Market from 2014 to 2019

      • 6.1.2 Top 5 Export Countries’ Export Volume Analysis in Recombinant Protein Drugs Market from 2014 to 2019

    • 6.2 Top 5 Import Countries in Recombinant Protein Drugs Market from 2014 to 2019

      • 6.2.1 Top 5 Import Countries’ Import Value Analysis in Recombinant Protein Drugs Market from 2014 to 2019

      • 6.2.2 Top 5 Import Countries’ Import Volume Analysis in Recombinant Protein Drugs Market from 2014 to 2019

    • 6.3 Emerging Top 3 Export Countries Analysis

    • 6.4 Emerging Top 3 Import Countries Analysis

    7. Germany Recombinant Protein Drugs Landscape Analysis

    • 7.1 Germany Recombinant Protein Drugs Landscape Analysis by Major Types

    • 7.2 Germany Recombinant Protein Drugs Landscape Analysis by Major End-Users

    8. UK Recombinant Protein Drugs Landscape Analysis

    • 8.1 UK Recombinant Protein Drugs Landscape Analysis by Major Types

    • 8.2 UK Recombinant Protein Drugs Landscape Analysis by Major End-Users

    9. France Recombinant Protein Drugs Landscape Analysis

    • 9.1 France Recombinant Protein Drugs Landscape Analysis by Major Types

    • 9.2 France Recombinant Protein Drugs Landscape Analysis by Major End-Users

    10. Italy Recombinant Protein Drugs Landscape Analysis

    • 10.1 Italy Recombinant Protein Drugs Landscape Analysis by Major Types

    • 10.2 Italy Recombinant Protein Drugs Landscape Analysis by Major End-Users

    11. Spain Recombinant Protein Drugs Landscape Analysis

    • 11.1 Spain Recombinant Protein Drugs Landscape Analysis by Major Types

    • 11.2 Spain Recombinant Protein Drugs Landscape Analysis by Major End-Users

    12. Poland Recombinant Protein Drugs Landscape Analysis

    • 12.1 Poland Recombinant Protein Drugs Landscape Analysis by Major Types

    • 12.2 Poland Recombinant Protein Drugs Landscape Analysis by Major End-Users

    13. Russia Recombinant Protein Drugs Landscape Analysis

    • 13.1 Russia Recombinant Protein Drugs Landscape Analysis by Major Types

    • 13.2 Russia Recombinant Protein Drugs Landscape Analysis by Major End-Users

    14. Switzerland Recombinant Protein Drugs Landscape Analysis

    • 14.1 Switzerland Recombinant Protein Drugs Landscape Analysis by Major Types

    • 14.2 Switzerland Recombinant Protein Drugs Landscape Analysis by Major End-Users

    15. Turkey Recombinant Protein Drugs Landscape Analysis

    • 15.1 Turkey Recombinant Protein Drugs Landscape Analysis by Major Types

    • 15.2 Turkey Recombinant Protein Drugs Landscape Analysis by Major End-Users

    16. Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Recombinant Protein Drugs Landscape Analysis

    • 16.1 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Recombinant Protein Drugs Landscape Analysis by Major Types

    • 16.2 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Recombinant Protein Drugs Landscape Analysis by Major End-Users

    • 16.3 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Recombinant Protein Drugs Landscape Analysis by Top Countries

      • 16.3.1 Denmark Recombinant Protein Drugs Market Volume and Growth Rate

      • 16.3.2 Finland Recombinant Protein Drugs Market Volume and Growth Rate

      • 16.3.3 Norway Recombinant Protein Drugs Market Volume and Growth Rate

      • 16.3.4 Sweden Recombinant Protein Drugs Market Volume and Growth Rate

      • 16.3.6 Iceland Recombinant Protein Drugs Market Volume and Growth Rate

    17 Benelux (Belgium, Netherlands, and Luxembourg) Recombinant Protein Drugs Landscape Analysis

    • 17.1 Benelux (Belgium, Netherlands, and Luxembourg) Recombinant Protein Drugs Landscape Analysis by Major Types

    • 17.2 Benelux (Belgium, Netherlands, and Luxembourg) Recombinant Protein Drugs Landscape Analysis by Major End-Users

    • 17.3 Benelux (Belgium, Netherlands, and Luxembourg) Recombinant Protein Drugs Landscape Analysis by Top Countries

      • 17.3.1 Belgium Recombinant Protein Drugs Market Volume and Growth Rate

      • 17.3.2 Netherlands Recombinant Protein Drugs Market Volume and Growth Rate

      • 17.3.3 Luxembourg Recombinant Protein Drugs Market Volume and Growth Rate

    18 Baltic States (Estonia, Latvia, and Lithuania) Recombinant Protein Drugs Landscape Analysis

    • 18.1 Baltic States (Estonia, Latvia, and Lithuania) Recombinant Protein Drugs Landscape Analysis by Major Types

    • 18.2 Baltic States (Estonia, Latvia, and Lithuania) Recombinant Protein Drugs Landscape Analysis by Major End-Users

    • 18.3 Baltic States (Estonia, Latvia, and Lithuania) Recombinant Protein Drugs Landscape Analysis by Top Countries

      • 18.3.1 Estonia Recombinant Protein Drugs Market Volume and Growth Rate

      • 18.3.2 Latvia Recombinant Protein Drugs Market Volume and Growth Rate

      • 18.3.3 Lithuania Recombinant Protein Drugs Market Volume and Growth Rate

    19 Major Players Profiles

    • 19.1 Eli Lilly

      • 19.1.1 Eli Lilly Company Profile and Development Status

      • 19.1.2 Market Performance

      • 19.1.3 Product and Service Introduction

    • 19.2 SL PHARM

      • 19.2.1 SL PHARM Company Profile and Development Status

      • 19.2.2 Market Performance

      • 19.2.3 Product and Service Introduction

    • 19.3 Roche

      • 19.3.1 Roche Company Profile and Development Status

      • 19.3.2 Market Performance

      • 19.3.3 Product and Service Introduction

    • 19.4 Abcam

      • 19.4.1 Abcam Company Profile and Development Status

      • 19.4.2 Market Performance

      • 19.4.3 Product and Service Introduction

    • 19.5 Kyowa Hakko Kirin

      • 19.5.1 Kyowa Hakko Kirin Company Profile and Development Status

      • 19.5.2 Market Performance

      • 19.5.3 Product and Service Introduction

    • 19.6 Sanofi

      • 19.6.1 Sanofi Company Profile and Development Status

      • 19.6.2 Market Performance

      • 19.6.3 Product and Service Introduction

    • 19.7 Amgen

      • 19.7.1 Amgen Company Profile and Development Status

      • 19.7.2 Market Performance

      • 19.7.3 Product and Service Introduction

    • 19.8 Merck Serono

      • 19.8.1 Merck Serono Company Profile and Development Status

      • 19.8.2 Market Performance

      • 19.8.3 Product and Service Introduction

    • 19.9 Pharmingen

      • 19.9.1 Pharmingen Company Profile and Development Status

      • 19.9.2 Market Performance

      • 19.9.3 Product and Service Introduction

    • 19.10 Dongbao Pharm

      • 19.10.1 Dongbao Pharm Company Profile and Development Status

      • 19.10.2 Market Performance

      • 19.10.3 Product and Service Introduction

    • 19.11 NCPC

      • 19.11.1 NCPC Company Profile and Development Status

      • 19.11.2 Market Performance

      • 19.11.3 Product and Service Introduction

    • 19.12 Novo Nordisk

      • 19.12.1 Novo Nordisk Company Profile and Development Status

      • 19.12.2 Market Performance

      • 19.12.3 Product and Service Introduction

    • 19.13 Heng Rui

      • 19.13.1 Heng Rui Company Profile and Development Status

      • 19.13.2 Market Performance

      • 19.13.3 Product and Service Introduction

    • 19.14 Ankebio

      • 19.14.1 Ankebio Company Profile and Development Status

      • 19.14.2 Market Performance

      • 19.14.3 Product and Service Introduction

    • 19.15 GenSci

      • 19.15.1 GenSci Company Profile and Development Status

      • 19.15.2 Market Performance

      • 19.15.3 Product and Service Introduction

    • 19.16 Ortho Biotech

      • 19.16.1 Ortho Biotech Company Profile and Development Status

      • 19.16.2 Market Performance

      • 19.16.3 Product and Service Introduction

    The List of Tables and Figures (Totals 104 Figures and 189 Tables)

    • Figure Product Picture

    • Figure Recombinant Protein Drugs Market Size and Growth Rate of Recombinant DNA Market, 2015 - 2026 (USD Million)

    • Figure Recombinant Protein Drugs Market Size and Growth Rate of Recombinant RNA Market, 2015 - 2026 (USD Million)

    • Figure Recombinant Protein Drugs Market Size and Growth Rate of Polymer and Petrochemicals from 2014 to 2026

    • Figure Recombinant Protein Drugs Market Size and Growth Rate of Pharmaceuticals from 2014 to 2026

    • Figure Recombinant Protein Drugs Market Size and Growth Rate of Electronics from 2014 to 2026

    • Figure Recombinant Protein Drugs Market Size and Growth Rate of Agrochemicals from 2014 to 2026

    • Figure Recombinant Protein Drugs Market Size and Growth Rate of Others from 2014 to 2026

    • Figure Germany Recombinant Protein Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure UK Recombinant Protein Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure France Recombinant Protein Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Italy Recombinant Protein Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Spain Recombinant Protein Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Poland Recombinant Protein Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Russia Recombinant Protein Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Switzerland Recombinant Protein Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Turkey Recombinant Protein Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Canada Recombinant Protein Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Mexico Recombinant Protein Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Recombinant Protein Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Denmark Recombinant Protein Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Finland Recombinant Protein Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Norway Recombinant Protein Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Sweden Recombinant Protein Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Iceland Recombinant Protein Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Benelux (Belgium, Netherlands, and Luxembourg) Recombinant Protein Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Belgium Recombinant Protein Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Netherlands Recombinant Protein Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Luxembourg Recombinant Protein Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Baltic States (Estonia, Latvia, and Lithuania) Recombinant Protein Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Estonia Recombinant Protein Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Latvia Recombinant Protein Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Lithuania Recombinant Protein Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Development Trends and Industry Dynamics of Recombinant Protein Drugs Industry

    • Figure Market Challenges and Restraints

    • Figure Market Opportunities and Potentials

    • Table Mergers and Acquisition

    • Figure Market Share of TOP 6 Players from 2014 to 2019

    • Figure Porter's Five Forces Analysis

    • Figure New Entrant SWOT Analysis

    • Table Specifications of Different Types of Recombinant Protein Drugs

    • Figure Development Trends of Different Types

    • Table Commercial Products Types of Major Vendors

    • Figure Competitive Landscape Analysis of Different Types

    • Table Consumption of Recombinant Protein Drugs by Different Types from 2014 to 2026

    • Table Consumption Share of Recombinant Protein Drugs by Different Types from 2014 to 2026

    • Figure Recombinant Protein Drugs Market Size and Growth Rate of Recombinant DNA Market, 2015 - 2026 (USD Million)

    • Figure Recombinant Protein Drugs Market Size and Growth Rate of Recombinant RNA Market, 2015 - 2026 (USD Million)

    • Table Downstream Client Analysis by End-Users

    • Figure Competitive Landscape Analysis of Different End-Users

    • Table Market Potential Analysis of Different End-Users

    • Table Consumption of Recombinant Protein Drugs by Different End-Users from 2014 to 2026

    • Table Consumption Share of Recombinant Protein Drugs by Different End-Users from 2014 to 2026

    • Figure Recombinant Protein Drugs Market Size and Growth Rate of Polymer and Petrochemicals from 2014 to 2026

    • Figure Recombinant Protein Drugs Market Size and Growth Rate of Pharmaceuticals from 2014 to 2026

    • Figure Recombinant Protein Drugs Market Size and Growth Rate of Electronics from 2014 to 2026

    • Figure Recombinant Protein Drugs Market Size and Growth Rate of Agrochemicals from 2014 to 2026

    • Figure Recombinant Protein Drugs Market Size and Growth Rate of Others from 2014 to 2026

    • Table Europe Recombinant Protein Drugs Production by Major Regions

    • Table Europe Recombinant Protein Drugs Production Share by Major Regions

    • Figure Europe Recombinant Protein Drugs Production Share by Major Countries and Regions in 2014

    • Table Europe Recombinant Protein Drugs Consumption by Major Regions

    • Table Europe Recombinant Protein Drugs Consumption Share by Major Regions

    • Table Germany Recombinant Protein Drugs Production, Import, Consumption and Export Analysis

    • Table UK Recombinant Protein Drugs Production, Import, Consumption and Export Analysis

    • Table France Recombinant Protein Drugs Production, Import, Consumption and Export Analysis

    • Table Italy Recombinant Protein Drugs Production, Import, Consumption and Export Analysis

    • Table Spain Recombinant Protein Drugs Production, Import, Consumption and Export Analysis

    • Table Poland Recombinant Protein Drugs Production, Import, Consumption and Export Analysis

    • Table Russia Recombinant Protein Drugs Production, Import, Consumption and Export Analysis

    • Table Switzerland Recombinant Protein Drugs Production, Import, Consumption and Export Analysis

    • Table Turkey Recombinant Protein Drugs Production, Import, Consumption and Export Analysis

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Recombinant Protein Drugs Production, Import, Consumption and Export Analysis

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Recombinant Protein Drugs Production, Import, Consumption and Export Analysis

    • Table Baltic States (Estonia, Latvia, and Lithuania) Recombinant Protein Drugs Production, Import, Consumption and Export Analysis

    • Table Top 5 Export Countries' Export Value Analysis in Recombinant Protein Drugs Market from 2014 to 2019

    • Table Top 5 Export Countries' Export Volume Analysis in Recombinant Protein Drugs Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Value Analysis in Recombinant Protein Drugs Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Volume Analysis in Recombinant Protein Drugs Market from 2014 to 2019

    • Figure Emerging Top 3 Export Countries Analysis

    • Figure Emerging Top 3 Import Countries Analysis

    • Table Germany Recombinant Protein Drugs Consumption by Types from 2014 to 2026

    • Table Germany Recombinant Protein Drugs Consumption Share by Types from 2014 to 2026

    • Table Germany Recombinant Protein Drugs Consumption by End-Users from 2014 to 2026

    • Table Germany Recombinant Protein Drugs Consumption Share by End-Users from 2014 to 2026

    • Table UK Recombinant Protein Drugs Consumption by Types from 2014 to 2026

    • Table UK Recombinant Protein Drugs Consumption Share by Types from 2014 to 2026

    • Table UK Recombinant Protein Drugs Consumption by End-Users from 2014 to 2026

    • Table UK Recombinant Protein Drugs Consumption Share by End-Users from 2014 to 2026

    • Table France Recombinant Protein Drugs Consumption by Types from 2014 to 2026

    • Table France Recombinant Protein Drugs Consumption Share by Types from 2014 to 2026

    • Table France Recombinant Protein Drugs Consumption by End-Users from 2014 to 2026

    • Table France Recombinant Protein Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Italy Recombinant Protein Drugs Consumption by Types from 2014 to 2026

    • Table Italy Recombinant Protein Drugs Consumption Share by Types from 2014 to 2026

    • Table Italy Recombinant Protein Drugs Consumption by End-Users from 2014 to 2026

    • Table Italy Recombinant Protein Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Spain Recombinant Protein Drugs Consumption by Types from 2014 to 2026

    • Table Spain Recombinant Protein Drugs Consumption Share by Types from 2014 to 2026

    • Table Spain Recombinant Protein Drugs Consumption by End-Users from 2014 to 2026

    • Table Spain Recombinant Protein Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Poland Recombinant Protein Drugs Consumption by Types from 2014 to 2026

    • Table Poland Recombinant Protein Drugs Consumption Share by Types from 2014 to 2026

    • Table Poland Recombinant Protein Drugs Consumption by End-Users from 2014 to 2026

    • Table Poland Recombinant Protein Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Russia Recombinant Protein Drugs Consumption by Types from 2014 to 2026

    • Table Russia Recombinant Protein Drugs Consumption Share by Types from 2014 to 2026

    • Table Russia Recombinant Protein Drugs Consumption by End-Users from 2014 to 2026

    • Table Russia Recombinant Protein Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Switzerland Recombinant Protein Drugs Consumption by Types from 2014 to 2026

    • Table Switzerland Recombinant Protein Drugs Consumption Share by Types from 2014 to 2026

    • Table Switzerland Recombinant Protein Drugs Consumption by End-Users from 2014 to 2026

    • Table Switzerland Recombinant Protein Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Turkey Recombinant Protein Drugs Consumption by Types from 2014 to 2026

    • Table Turkey Recombinant Protein Drugs Consumption Share by Types from 2014 to 2026

    • Table Turkey Recombinant Protein Drugs Consumption by End-Users from 2014 to 2026

    • Table Turkey Recombinant Protein Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Recombinant Protein Drugs Consumption by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Recombinant Protein Drugs Consumption Share by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Recombinant Protein Drugs Consumption by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Recombinant Protein Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Recombinant Protein Drugs Consumption by Major Countries from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Recombinant Protein Drugs Consumption Share by Major Countries from 2014 to 2026

    • Figure Denmark Recombinant Protein Drugs Market Volume and Growth Rate from 2014 to 2026

    • Figure Finland Recombinant Protein Drugs Market Volume and Growth Rate from 2014 to 2026

    • Figure Norway Recombinant Protein Drugs Market Volume and Growth Rate from 2014 to 2026

    • Figure Sweden Recombinant Protein Drugs Market Volume and Growth Rate from 2014 to 2026

    • Figure Iceland Recombinant Protein Drugs Market Volume and Growth Rate from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Recombinant Protein Drugs Consumption by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Recombinant Protein Drugs Consumption Share by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Recombinant Protein Drugs Consumption by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Recombinant Protein Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Recombinant Protein Drugs Consumption by Major Countries from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Recombinant Protein Drugs Consumption Share by Major Countries from 2014 to 2026

    • Figure Belgium Recombinant Protein Drugs Market Volume and Growth Rate from 2014 to 2026

    • Figure Netherlands Recombinant Protein Drugs Market Volume and Growth Rate from 2014 to 2026

    • Figure Luxembourg Recombinant Protein Drugs Market Volume and Growth Rate from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Recombinant Protein Drugs Consumption by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Recombinant Protein Drugs Consumption Share by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Recombinant Protein Drugs Consumption by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Recombinant Protein Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Recombinant Protein Drugs Consumption by Major Countries from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Recombinant Protein Drugs Consumption Share by Major Countries from 2014 to 2026

    • Figure Estonia Recombinant Protein Drugs Market Volume and Growth Rate from 2014 to 2026

    • Figure Latvia Recombinant Protein Drugs Market Volume and Growth Rate from 2014 to 2026

    • Figure Lithuania Countries Recombinant Protein Drugs Market Volume and Growth Rate from 2014 to 2026

    • Table Eli Lilly Profiles

    • Table Eli Lilly Production, Value, Price, Gross Margin 2014-2019

    • Table Eli Lilly Product benchmarking

    • Table Eli Lilly Strategic initiatives

    • Table Eli Lilly SWOT analysis

    • Table SL PHARM Profiles

    • Table SL PHARM Production, Value, Price, Gross Margin 2014-2019

    • Table SL PHARM Product benchmarking

    • Table SL PHARM Strategic initiatives

    • Table SL PHARM SWOT analysis

    • Table Roche Profiles

    • Table Roche Production, Value, Price, Gross Margin 2014-2019

    • Table Roche Product benchmarking

    • Table Roche Strategic initiatives

    • Table Roche SWOT analysis

    • Table Abcam Profiles

    • Table Abcam Production, Value, Price, Gross Margin 2014-2019

    • Table Abcam Product benchmarking

    • Table Abcam Strategic initiatives

    • Table Abcam SWOT analysis

    • Table Kyowa Hakko Kirin Profiles

    • Table Kyowa Hakko Kirin Production, Value, Price, Gross Margin 2014-2019

    • Table Kyowa Hakko Kirin Product benchmarking

    • Table Kyowa Hakko Kirin Strategic initiatives

    • Table Kyowa Hakko Kirin SWOT analysis

    • Table Sanofi Profiles

    • Table Sanofi Production, Value, Price, Gross Margin 2014-2019

    • Table Sanofi Product benchmarking

    • Table Sanofi Strategic initiatives

    • Table Sanofi SWOT analysis

    • Table Amgen Profiles

    • Table Amgen Production, Value, Price, Gross Margin 2014-2019

    • Table Amgen Product benchmarking

    • Table Amgen Strategic initiatives

    • Table Amgen SWOT analysis

    • Table Merck Serono Profiles

    • Table Merck Serono Production, Value, Price, Gross Margin 2014-2019

    • Table Merck Serono Product benchmarking

    • Table Merck Serono Strategic initiatives

    • Table Merck Serono SWOT analysis

    • Table Pharmingen Profiles

    • Table Pharmingen Production, Value, Price, Gross Margin 2014-2019

    • Table Pharmingen Product benchmarking

    • Table Pharmingen Strategic initiatives

    • Table Pharmingen SWOT analysis

    • Table Dongbao Pharm Profiles

    • Table Dongbao Pharm Production, Value, Price, Gross Margin 2014-2019

    • Table Dongbao Pharm Product benchmarking

    • Table Dongbao Pharm Strategic initiatives

    • Table Dongbao Pharm SWOT analysis

    • Table NCPC Profiles

    • Table NCPC Production, Value, Price, Gross Margin 2014-2019

    • Table NCPC Product benchmarking

    • Table NCPC Strategic initiatives

    • Table NCPC SWOT analysis

    • Table Novo Nordisk Profiles

    • Table Novo Nordisk Production, Value, Price, Gross Margin 2014-2019

    • Table Novo Nordisk Product benchmarking

    • Table Novo Nordisk Strategic initiatives

    • Table Novo Nordisk SWOT analysis

    • Table Heng Rui Profiles

    • Table Heng Rui Production, Value, Price, Gross Margin 2014-2019

    • Table Heng Rui Product benchmarking

    • Table Heng Rui Strategic initiatives

    • Table Heng Rui SWOT analysis

    • Table Ankebio Profiles

    • Table Ankebio Production, Value, Price, Gross Margin 2014-2019

    • Table Ankebio Product benchmarking

    • Table Ankebio Strategic initiatives

    • Table Ankebio SWOT analysis

    • Table GenSci Profiles

    • Table GenSci Production, Value, Price, Gross Margin 2014-2019

    • Table GenSci Product benchmarking

    • Table GenSci Strategic initiatives

    • Table GenSci SWOT analysis

    • Table Ortho Biotech Profiles

    • Table Ortho Biotech Production, Value, Price, Gross Margin 2014-2019

    • Table Ortho Biotech Product benchmarking

    • Table Ortho Biotech Strategic initiatives

    • Table Ortho Biotech SWOT analysis

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US